CN104803997A - 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 - Google Patents
酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 Download PDFInfo
- Publication number
- CN104803997A CN104803997A CN201510100478.6A CN201510100478A CN104803997A CN 104803997 A CN104803997 A CN 104803997A CN 201510100478 A CN201510100478 A CN 201510100478A CN 104803997 A CN104803997 A CN 104803997A
- Authority
- CN
- China
- Prior art keywords
- casein kinase
- compound
- disease
- kinase
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC1C(c2ccc(N)[n]2)=C(C2)CC2/C(/C)=*/C1=O Chemical compound CC1C(c2ccc(N)[n]2)=C(C2)CC2/C(/C)=*/C1=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (9)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010178549 | 2010-08-09 | ||
JP2010-178549 | 2010-08-09 | ||
CN201180039427.7A CN103097380B (zh) | 2010-08-09 | 2011-08-08 | 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180039427.7A Division CN103097380B (zh) | 2010-08-09 | 2011-08-08 | 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104803997A true CN104803997A (zh) | 2015-07-29 |
Family
ID=45567692
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180039427.7A Active CN103097380B (zh) | 2010-08-09 | 2011-08-08 | 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 |
CN201510100478.6A Pending CN104803997A (zh) | 2010-08-09 | 2011-08-08 | 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180039427.7A Active CN103097380B (zh) | 2010-08-09 | 2011-08-08 | 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8710231B2 (zh) |
EP (1) | EP2604606B1 (zh) |
JP (1) | JP5181156B2 (zh) |
KR (1) | KR101856266B1 (zh) |
CN (2) | CN103097380B (zh) |
AU (1) | AU2011290238B8 (zh) |
CA (1) | CA2807359C (zh) |
HK (2) | HK1183874A1 (zh) |
IL (1) | IL224612A (zh) |
RU (1) | RU2562833C2 (zh) |
WO (1) | WO2012020726A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112601744A (zh) * | 2018-07-05 | 2021-04-02 | 拜耳公司 | 作为抗菌剂的取代的噻吩甲酰胺及类似物 |
CN113301900A (zh) * | 2018-09-09 | 2021-08-24 | 夸纳特制药股份公司 | 酪蛋白激酶1抑制剂在治疗血管疾病中的应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101856266B1 (ko) * | 2010-08-09 | 2018-05-09 | 가부시키가이샤 에누비 켄코우겡큐쇼 | 카세인 키나아제 1δ 및 카세인 키나아제 1ε 저해제 |
US20230053307A1 (en) * | 2021-07-19 | 2023-02-16 | Buddhist Tzu Chi Medical Foundation | Method for preventing or treating skin disorders and conditions |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101039666A (zh) * | 2004-08-19 | 2007-09-19 | 安万特药物公司 | 作为酪蛋白激酶Iε抑制剂的3-芳基硫代吲哚-2-甲酰胺衍生物及其类似物 |
WO2010092660A1 (ja) * | 2009-02-12 | 2010-08-19 | 株式会社ファルマデザイン | カゼインキナーゼ1δ及びカゼインキナーゼ1ε阻害剤 |
CN103097380A (zh) * | 2010-08-09 | 2013-05-08 | 株式会社创药分子设计 | 酪蛋白激酶1δ 及酪蛋白激酶1ε 抑制剂 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2819508B1 (fr) * | 2001-01-12 | 2005-01-21 | Sod Conseils Rech Applic | Derives de 2-arylimino-2, 3-dihydorthiazoles, leurs procedes de preparation et leur utilisation therapeutiques |
FR2796643B1 (fr) * | 1999-07-22 | 2005-04-29 | Sod Conseils Rech Applic | Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique |
US7041685B2 (en) | 2001-06-08 | 2006-05-09 | Cytovia, Inc. | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
MY140489A (en) * | 2003-12-26 | 2009-12-31 | Eisai R&D Man Co Ltd | 1,2-di (cyclic) substituted benzene compounds |
AR049769A1 (es) * | 2004-01-22 | 2006-09-06 | Novartis Ag | Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina |
JO2629B1 (en) * | 2004-08-19 | 2012-06-24 | افينتيس فارما سوتيكالز انك | Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon |
US7531539B2 (en) * | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
FR2918986B1 (fr) * | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
JP2009245477A (ja) | 2008-03-28 | 2009-10-22 | Hoya Corp | 垂直磁気記録媒体 |
-
2011
- 2011-08-08 KR KR1020137005642A patent/KR101856266B1/ko active IP Right Grant
- 2011-08-08 US US13/816,180 patent/US8710231B2/en active Active
- 2011-08-08 RU RU2013107659/04A patent/RU2562833C2/ru active
- 2011-08-08 CN CN201180039427.7A patent/CN103097380B/zh active Active
- 2011-08-08 EP EP11816390.6A patent/EP2604606B1/en active Active
- 2011-08-08 CN CN201510100478.6A patent/CN104803997A/zh active Pending
- 2011-08-08 WO PCT/JP2011/068034 patent/WO2012020726A1/ja active Application Filing
- 2011-08-08 CA CA2807359A patent/CA2807359C/en active Active
- 2011-08-08 AU AU2011290238A patent/AU2011290238B8/en active Active
- 2011-08-08 JP JP2012528666A patent/JP5181156B2/ja active Active
-
2013
- 2013-02-07 IL IL224612A patent/IL224612A/en active IP Right Grant
- 2013-10-10 HK HK13111396.2A patent/HK1183874A1/zh unknown
-
2015
- 2015-12-25 HK HK15112726.9A patent/HK1211926A1/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101039666A (zh) * | 2004-08-19 | 2007-09-19 | 安万特药物公司 | 作为酪蛋白激酶Iε抑制剂的3-芳基硫代吲哚-2-甲酰胺衍生物及其类似物 |
JP2008510704A (ja) * | 2004-08-19 | 2008-04-10 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | カゼインキナーゼIεの阻害剤としての3−アリールチオインドール−2−カルボキサミド誘導体及びその類似体 |
WO2010092660A1 (ja) * | 2009-02-12 | 2010-08-19 | 株式会社ファルマデザイン | カゼインキナーゼ1δ及びカゼインキナーゼ1ε阻害剤 |
CN103097380A (zh) * | 2010-08-09 | 2013-05-08 | 株式会社创药分子设计 | 酪蛋白激酶1δ 及酪蛋白激酶1ε 抑制剂 |
Non-Patent Citations (2)
Title |
---|
MASAKO OKAMOTO ET AL.: "Structure-activity relationship of novel DAPK inhibitors identified by structure-based virtual screening", 《BIOORGANIC & MEDICINAL CHEMISTRY》 * |
R.B 西尔弗曼 编,郭宗儒 主译: "《有机药物化学》", 31 January 2008 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112601744A (zh) * | 2018-07-05 | 2021-04-02 | 拜耳公司 | 作为抗菌剂的取代的噻吩甲酰胺及类似物 |
CN112601744B (zh) * | 2018-07-05 | 2024-03-29 | 拜耳公司 | 作为抗菌剂的取代的噻吩甲酰胺及类似物 |
CN113301900A (zh) * | 2018-09-09 | 2021-08-24 | 夸纳特制药股份公司 | 酪蛋白激酶1抑制剂在治疗血管疾病中的应用 |
Also Published As
Publication number | Publication date |
---|---|
JP5181156B2 (ja) | 2013-04-10 |
CA2807359C (en) | 2020-07-07 |
US8710231B2 (en) | 2014-04-29 |
KR20140000666A (ko) | 2014-01-03 |
IL224612A (en) | 2016-05-31 |
AU2011290238A1 (en) | 2013-03-21 |
AU2011290238B2 (en) | 2014-07-17 |
WO2012020726A1 (ja) | 2012-02-16 |
KR101856266B1 (ko) | 2018-05-09 |
HK1211926A1 (zh) | 2016-06-03 |
CN103097380A (zh) | 2013-05-08 |
EP2604606B1 (en) | 2014-10-08 |
CA2807359A1 (en) | 2012-02-16 |
US20130137730A1 (en) | 2013-05-30 |
RU2562833C2 (ru) | 2015-09-10 |
CN103097380B (zh) | 2015-06-03 |
HK1183874A1 (zh) | 2014-01-10 |
AU2011290238B8 (en) | 2015-09-03 |
EP2604606A1 (en) | 2013-06-19 |
EP2604606A4 (en) | 2013-08-07 |
JPWO2012020726A1 (ja) | 2013-10-28 |
RU2013107659A (ru) | 2014-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7812025B2 (en) | Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder | |
JP2024037891A (ja) | 黒色腫の治療のための組合せ医薬 | |
CN104395319A (zh) | 用作ampk的活化剂的噻吩并吡啶酮衍生物 | |
JP2013527177A (ja) | 代謝を調節する組成物および方法 | |
CN101792417A (zh) | 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物 | |
BR112020026062A2 (pt) | derivados de benzodiazepina, composições, e métodos para o tratamento de comprometimento cognitivo | |
CN103957916A (zh) | 用于治疗代谢疾病和相关失调的单酰甘油脂肪酶抑制剂 | |
CN103097380B (zh) | 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 | |
CN103380112A (zh) | 作为s1p受体调节剂的吲哚衍生物 | |
US8765953B2 (en) | Compounds and methods for the treatment of pain and other diseases | |
US9018238B2 (en) | Inhibitor of casein kinase 1δ and casein kinase 1ε | |
WO2015163431A1 (ja) | 片頭痛治療剤 | |
WO2017119455A1 (ja) | 自閉症スペクトラム障害の予防または治療剤 | |
CN112300145A (zh) | 一类靶向stat3双功能磷酸化位点的三芳香环类化合物及其应用 | |
TW200410937A (en) | 3-imino-2-indolones for the treatment of depression and/or anxiety | |
CN114761382A (zh) | Magl抑制剂的晶型 | |
EP3569233A1 (en) | Therapeutic agent for non-motor symptoms associated with parkinson's disease | |
JP2014201578A (ja) | 線維筋痛症治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: NB HEALTH LAB CO., LTD. Effective date: 20150827 Owner name: NB HEALTH LAB CO., LTD. Free format text: FORMER OWNER: PHARMA DESIGN INC Effective date: 20150827 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150827 Address after: Hokkaido Japan Applicant after: NB Health Laboratory Co. Ltd. Address before: Tokyo, Japan, Japan Applicant before: Pharmadesign, Inc. Applicant before: NB Health Laboratory Co. Ltd. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1211926 Country of ref document: HK |
|
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150729 |
|
WD01 | Invention patent application deemed withdrawn after publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1211926 Country of ref document: HK |